PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

Oncogene

Volumn 35, Issue 27, 2016, Pages 3607-3612

  Wang, Q ^a,b,d   Liu, P ^a,c   Spangle, J M ^a,b   Von, T ^a,b   Roberts, T M ^a,b   Lin, N U ^a   Krop, I E ^a   Winer, E P ^a   Zhao, J J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P110; PROTEIN P110 ALPHA; PROTEIN P110 BETA; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; NVP-BYL719; PIK3CA PROTEIN, HUMAN; PIK3CB PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE ACTIVATION; GENE DELETION; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; KNOCKOUT MOUSE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84977663948     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.406     Document Type: Article

References (27)

1. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
2. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
3. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
4. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11: 329-341.
5. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 2006; 103: 16296-16300.
6. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-666.
7. Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC et al. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 2012; 26: 1573-1586.
8. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 2008; 105: 8292-8297.
9. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-779.
10. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
11. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091.
12. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
13. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sanchez V et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA 2013; 110: 14372-14377.
14. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
15. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
16. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177: 1647-1656.
17. Vanhaesebroeck B, Khwaja A. PI3Kdelta inhibition hits a sensitive spot in B cell malignancies. Cancer Cell 2014; 25: 269-271.
18. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156.
19. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008; 105: 13057-13062.
20. Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, Cardiff RD et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 2009; 284: 19018-19026.
21. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT et al. Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 2015; 27: 97-108.
22. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell 2015; 27: 109-122.
23. Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM et al. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci USA 2014; 111: 6395-6400.
24. Juric D, Krop I, Ramanathan R, Xiao J, Sanabria S, Wilson T et al. Lbstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase 1a dose escalation study. Cancer Res 2013; 73: 6.
25. Juric D, Rodon J, Gonzalez-Angulo A, Burris H, Bendell J, Berlin J et al. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 2012; 72: 6.
26. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008; 27: 910-920.
27. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32: 148-149.